Drugs / MUTAGRIP
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02960815 | Nov 2016 → Jun 2017 | — | University of Lausanne Hospitals | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01022749 | Sep 2009 → Jul 2011 | inflammatory bowel disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01065285 | Oct 2009 → Jul 2011 | autoimmune disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT02746783 Comparator | Oct 2013 → Jul 2015 | — | University of Lausanne Hospitals | Completed | No outcome recorded |
| Phase 4 | NCT00757900 Comparator | Apr → Sep 2008 | HIV infectious disease, influenza | University of Witwatersrand, South Africa | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUTAGRIP | “Subjects received SFV (1 dose, Mutagrip®) and/or non-adjuvant HFV (Panenza®, 2 doses at a 3-week interval).” PMID 22640652 ↗ May 20124“MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)” NCT01022749 ↗ |
| Modality | Vaccine | “sub-unit influenza vaccine” NCT00757900 ↗ |
| Route | Intramuscular | “intramuscular route” NCT00757900 ↗ |